BMO Capital analyst Matthew Luchini initiates coverage on Gilead Sciences (NASDAQ: GILD) with a Outperform rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage